Live price temporarily unavailable.
Kyverna Therapeutics (KYTX) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$62.4M | −$142.6M | −$169.8M |
| Net income | −$60.4M | −$127.5M | −$161.3M |
| EPS (diluted) | −$89.61 | −$3.33 | −$3.64 |
| Balance sheet | |||
| Cash and equivalents | $34.6M | $96.6M | $124.1M |
| Total assets | $75.2M | $304.6M | $293.8M |
| Total liabilities | $26.0M | $38.1M | $61.5M |
| Long-term debt | — | — | $24.7M |
| Shareholders' equity | −$13.1M | $266.6M | $232.3M |
| Cash flow | |||
| Operating cash flow | −$52.4M | −$114.3M | −$153.7M |
| Capital expenditure | $621.0K | $2.21M | $5.00K |
| Free cash flow | −$53.0M | −$116.5M | −$153.7M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$38.8M | −$41.0M | −$47.4M | −$44.4M | −$38.7M | −$39.3M | −$41.4M | −$39.6M |
| Net income | −$34.5M | −$37.5M | −$44.6M | −$42.1M | −$36.8M | −$37.8M | −$39.7M | −$38.3M |
| EPS (diluted) | −$0.80 | −$0.74 | −$1.03 | −$0.97 | −$0.85 | −$0.79 | −$0.66 | −$0.63 |
| Balance sheet | ||||||||
| Cash and equivalents | $104.7M | $96.6M | $56.9M | $53.4M | $34.2M | $124.1M | $32.2M | $31.8M |
| Total assets | $339.2M | $304.6M | $260.7M | $226.5M | $187.2M | $293.8M | $257.0M | $219.8M |
| Total liabilities | $36.5M | $38.1M | $36.6M | $42.1M | $35.2M | $61.5M | $61.4M | $54.3M |
| Long-term debt | — | — | — | — | — | $24.7M | — | $24.9M |
| Shareholders' equity | $302.7M | $266.6M | $224.0M | $184.4M | $151.9M | $232.3M | $195.6M | $165.5M |
| Cash flow | ||||||||
| Operating cash flow | −$27.5M | −$37.1M | −$44.9M | −$31.9M | −$43.3M | −$33.5M | −$41.6M | −$40.3M |
| Capital expenditure | $102.0K | $532.0K | $0 | $4.00K | $2.00K | −$1.00K | — | — |
| Free cash flow | −$27.6M | −$37.6M | −$44.9M | −$32.0M | −$43.3M | −$33.5M | — | — |
From Kyverna Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Kyverna Therapeutics in our feed yet.